Bone Morphogenic Protein (bmp) Or Derivative Patents (Class 514/8.8)
-
Patent number: 8343527Abstract: The invention provides photocrosslinkable, injectable, biodegradable oligo(poly(ethylene glycol) fumarate) (OPF) hydrogels made from the photopolymerization of an OPF macromer with UV light and a photoinitiator. Hydrogels with varying mechanical properties and water content can be made with changes in macromer and crosslinking agent concentration in a precursor solution. The biodegradable OPF hydrogels can be injected as a fluid into a bodily defect of any shape, may incorporate various therapeutic agents, e.g., cells and/or growth factors, and may be implanted via minimally invasive arthroscopic techniques.Type: GrantFiled: March 23, 2006Date of Patent: January 1, 2013Inventors: Mahrokh Dadsetan, Michael Yaszemski, Lichun Lu
-
Publication number: 20120328557Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: June 23, 2011Publication date: December 27, 2012Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Patent number: 8333960Abstract: The present invention relates to administering autologous uncultured cells into a diseased intervertebral disc.Type: GrantFiled: October 31, 2008Date of Patent: December 18, 2012Assignee: DePuy Spine, Inc.Inventors: Mohamed Attawia, Hassan Serhan, Thomas M. DiMauro, Melissa Grace, David Urbahns
-
Publication number: 20120316110Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.Type: ApplicationFiled: March 26, 2012Publication date: December 13, 2012Applicant: Ben-Gurion University of the NegevInventors: Smadar Cohen, Jonathan Leor
-
Publication number: 20120316111Abstract: The present disclosure relates to a method to stimulate endogenous BMP-2 up-regulation in a subject which method comprises administering to a subject an effective amount of one or more of the following compounds prazosin, quinacrine, emetine, apomorphine, and debrisoquine, whereby endogenous BMP-2 up-regulation is stimulated in said subject. The endogenous BMP-2 up-regulation may enhance bone formation and/or cartilage formation.Type: ApplicationFiled: June 8, 2011Publication date: December 13, 2012Applicant: SOUTHWEST RESEARCH INSTITUTEInventor: Jorge G. ROSSINI
-
Publication number: 20120308532Abstract: There is disclosed a composition formed by a reaction of at least one component A and at least one component B, wherein component A is selected from the group consisting of a compound comprising at least two thiol-groups and a disulfide derivative of a compound comprising at least two thiol groups, and wherein component B is a compound comprising at least two vinyl groups, for the manufacture of an implant for the treatment of a bone fracture. Advantages include that the adhesive patch formed by the composition will be solid in body fluid upon curing and will exhibit excellent mechanical strength. Advantages include that the composition is biocompatible, the material can be applied in small and inaccessible areas, the process requires less surgeon training, it solves drawback with open surgery, and it is possible to use cost effective materials and methods in the process.Type: ApplicationFiled: October 19, 2010Publication date: December 6, 2012Applicant: PROPPABORT ABInventors: Anders Hult, Michael Malkoch, Hans Von Holst, Axel Nordberg
-
Publication number: 20120309680Abstract: The invention relates to an oligodextran, chosen from dextrans whose average degree of polymerization is less than 10, modified by at least one substituent of general formula I: —R1-[[AA]-[R2]n]m??formula I It also relates to a pharmaceutical composition characterized in that it comprises an oligosaccharide according to the invention and an active ingredient is chosen from the group consisting of proteins, glycoproteins, peptides and non-peptide therapeutic molecules.Type: ApplicationFiled: May 10, 2012Publication date: December 6, 2012Applicant: ADOCIAInventors: Richard CHARVET, Remi SOULA, Olivier SOULA
-
Publication number: 20120301538Abstract: The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating-agents and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: May 31, 2012Publication date: November 29, 2012Inventors: Roland GORDON-BERESFORD, Vinciane Gaussin, Jean-Pierre Latere Dwan'isa, Christian Homsy
-
Patent number: 8309521Abstract: The present invention relates to a spacer, such as a polymeric spacer, for use with an implant device, e.g., a bone plate, for splinting a fracture of a bone. The spacer includes a body defining a bone healing surface, wherein at least a portion of the bone healing surface has a coating which includes a therapeutic agent, a polymeric carrier, and a buffer medium to stimulate bone growth and/or promote fracture healing. A kit is also disclosed which includes one or more of the spacers, at least one bone plate, and optionally one or more bone screws for securing the bone plate to bone. A method for promoting fracture healing in bone is further disclosed which includes securely situating a coated portion of the spacer adjacent bone.Type: GrantFiled: June 19, 2007Date of Patent: November 13, 2012Assignee: Zimmer, Inc.Inventors: Kai Zhang, Daniel Buehler, Hallie E. Brinkerhuff, Michael E. Hawkins, Ralf Klabunde
-
Patent number: 8309518Abstract: Bioactive molecules are entrapped within a matrix for the controlled delivery of these compounds for therapeutic healing applications. The matrix may be formed of natural or synthetic compounds. The primary method of entrapment of the bioactive molecule is through precipitation of the bioactive molecule during gelation of the matrix, either in vitro or in vivo. The bioactive molecule may be modified to reduce its effective solubility in the matrix to retain it more effectively within the matrix, such as through the deglycosylation of members within the cystine knot growth factor superfamily and particularly within the TGF? superfamily. The matrix may be modified to include sites with binding affinity for different bioactive molecules, for example, for heparin binding.Type: GrantFiled: July 28, 2010Date of Patent: November 13, 2012Assignees: Eidgenossische Technische Hochschule Zurich, Universitat ZurichInventors: Jason C. Schense, Hugo Schmoekel, Jeffrey A. Hubbell, Franz Weber
-
Publication number: 20120282300Abstract: The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.Type: ApplicationFiled: March 30, 2012Publication date: November 8, 2012Applicant: GEL-DEL TECHNOLOGIES, INC.Inventors: David B. Masters, Eric P. Berg
-
Publication number: 20120277152Abstract: An embodiment of the present invention may be made by the following steps: providing a mixture comprising a plurality of fibers, a lubricant, and a suspension fluid, with the suspension fluid filling a void space between said fibers and subjecting said mixture to at least one compressive force. The compressive force causes the migration and alignment of said fibers; and may remove substantially all of the suspension fluid from said mixture. The mixture may further comprise a biologically active agent, or a reinforcing agent.Type: ApplicationFiled: March 13, 2012Publication date: November 1, 2012Inventors: Timothy A. Ringeisen, W. Christian Wattengel
-
Publication number: 20120276069Abstract: The invention relates to composition comprising a dextran-tyramine conjugate and a conjugate selected from the group consisting of chondroitin sulphate-tyramine, collagen-tyramine, chitosan-tyramine, chitosan-phloretic acid, gelatine-tyramine, heparan sulphate-tyramine, keratin sulphate-tyramine, hyaluronic acid-tyramine and heparin-tyramine.Type: ApplicationFiled: November 11, 2010Publication date: November 1, 2012Inventors: Hermanus Bernardus Johannes Karperien, Rong Jin, Liliana Sofia Moreira Teixeira, Jan Feijen, Pieter Jelle Dijkstra
-
Publication number: 20120258917Abstract: The present invention is directed to methods and compositions for accomplishing systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-? superfamily via a peripheral mode of administration. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the peripheral site of intravenous administration of the bioactive agent.Type: ApplicationFiled: April 11, 2012Publication date: October 11, 2012Inventors: Mary Elizabeth Pecquet Goad, Melissa M. Haskell, Denis Schrier, Susan A. Wood
-
Publication number: 20120258160Abstract: Cellulose and sulfated cellulose fibrous meshes exhibiting robust structural and mechanical integrity in water were fabricated using a combination of electrospinning, thermal-mechanical annealing and chemical modifications. The sulfated fibrous mesh exhibited higher retention capacity for human recombinant bone morphogenetic protein-2 than the cellulose mesh, and the retained proteins remained biologically active for at least 7 days. The sulfated fibrous mesh also more readily supported the attachment and osteogenic differentiation of rat bone marrow stromal cells in the absence of osteogenic growth factors. These properties combined make the sulfated cellulose fibrous mesh a promising bone tissue engineering scaffold.Type: ApplicationFiled: April 3, 2012Publication date: October 11, 2012Inventors: Jie Song, Tera Marie Fillion Potts, Artem Kutikov
-
Publication number: 20120258148Abstract: Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.Type: ApplicationFiled: June 8, 2012Publication date: October 11, 2012Inventors: Pierre DESCOUTS, Björn-Owe ARONSSON, Michael GRÄTZEL, Carine VIORNERY, Peter PÉCHY
-
Publication number: 20120244111Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using a pheromone, a luteinizing hormone (LH) and/or a human chorionic gonadotrophin (hCG). The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from or suspected of having neurodegenerative diseases or conditions.Type: ApplicationFiled: June 11, 2012Publication date: September 27, 2012Applicant: Stem Cell Therapeutics Corp.Inventors: Samuel WEISS, Emeka ENWERE, Linda ANDERSEN, Christopher GREGG
-
Publication number: 20120237525Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: December 10, 2010Publication date: September 20, 2012Applicant: ORTHOGEN AGInventors: Peter Wehling, Julio Reinecke
-
Publication number: 20120230942Abstract: The present invention relates to the expression and regulating growth factors in chrondrocytes and developing cartilage, particularly granulin-epithelin precursor (GEP). The invention relates to the modulation and manipulation of these growth factors, GEP, and/or the molecules they interact with, for instance COMP, in cartilage disorders, including arthritis. Assays and screening methods for the determination of the expression and activity of GEP, or of GEP-COMP, are provided, including for screening for the presence or extent of cartilage or arthritic disease and for identifying modulators or compounds/agents for treatment or prevention of cartilage or arthritic diseases.Type: ApplicationFiled: March 8, 2011Publication date: September 13, 2012Inventors: Chuanju Liu, Sally Frenkel
-
Publication number: 20120219497Abstract: A polymeric material comprised of (i) at least one random copolymer comprised of ethylene oxide and one or more other alkylene oxide(s) and (ii) at least one non-random polymer comprised of one or more poly(alkylene oxide)s has been discovered. Preferably, it is a polymer alloy. Alkylene oxide homo-polymers or block copolymers may be the non-random polymer. In a related discovery, an adhesive material can be made by suspending (a) particles in (b) a matrix of at least one poly(ethylene oxide) copolymer of ethylene oxide and propylene oxide, or a combination thereof. The handling characteristics may be adjusted for different utilities (e.g., from runny oil to hard wax). Applications include use as adhesive, cohesive, filler, lubricant, surfactant, or any combination thereof. In particular, the hard materials may be used for cleaning or waxing.Type: ApplicationFiled: February 27, 2012Publication date: August 30, 2012Applicant: SYNCERA, INC.Inventors: Tadeusz WELLISZ, Timothy C. Fisher, Jonathan K. Armstrong, John Cambridge
-
Publication number: 20120213782Abstract: In certain aspects, the present invention provides BMP10 propeptides for use in treating a variety of disorders including heart disorders and other disorders associated with unwanted activity of the mature BMP10 polypeptide. The present invention also provides methods of screening compounds that modulate activity of BMP10.Type: ApplicationFiled: April 9, 2012Publication date: August 23, 2012Applicant: Acceleron Pharma, Inc.Inventors: Jasbir Seehra, John Knopf
-
Publication number: 20120208753Abstract: The present invention relates to compositions comprising a modulator of GDF-6 signaling for the prevention of and/or treatment of a spinal disorder and/or spinal pain, eg., caused by and/or associated with intervertebral disc degeneration and methods of treatment of a spinal disorder and/or spinal pain comprising administering a modulator of GDF-6 signaling, or a composition comprising thereof.Type: ApplicationFiled: May 24, 2010Publication date: August 16, 2012Inventors: Ashish Diwan, Divya Diwan
-
Publication number: 20120202741Abstract: The present invention generally relates to delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist and methods of use thereof. In some embodiments, methods and devices are provided for delivery of BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist to a patient. In some cases, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be released in controlled fashion from a device in fluid communication with a patient. In some embodiments, the BMP-7 or functional variants or functional fragments thereof and/or a BMP-7 agonist may be expressed by cells within a device. In other embodiments, methods are provided for improving the function of devices containing renal proximal tubule cells.Type: ApplicationFiled: October 6, 2010Publication date: August 9, 2012Applicant: Agency for Science, Technology and ResearchInventors: Daniele Zink, Jackie Y. Ying, Edwin Pei Yong Chow, Farah Tasnim
-
Publication number: 20120195861Abstract: Described herein are the use of peripheral blood derived germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.Type: ApplicationFiled: January 14, 2011Publication date: August 2, 2012Applicant: The General Hospital CorporationInventors: Jonathan L. Tilly, Joshua Johnson
-
Publication number: 20120195952Abstract: Implantable matrices and methods are provided. The matrices are configured to fit at or near a target tissue site, the matrices comprise biodegradable materials and ligands bound to the matrices and are configured to bind receptors and allow influx of cells into the implantable matrices, wherein the ratio of ligands to receptors is from about 1.5 to about 0.5.Type: ApplicationFiled: January 31, 2011Publication date: August 2, 2012Applicant: WARSAW ORTHOPEDIC, INC.Inventor: Vanja Margareta King
-
Publication number: 20120195939Abstract: The present invention relates to pharmaceutical formulations suitable for targeting particular tissue and/or organ(s) with a formulated active ingredient, for example when administered upstream of the target organ or tissue, and to use of the same in treatment methods of preparing the formulations. The pharmaceutical formulations of the invention are for parenteral administration to a target tissue and comprise particles containing an active ingredient, and a biodegradable excipient, wherein 90% or more of the particles have a diameter of between 10 and 20 microns and the formulation is substantially free of particles with a diameter greater than 50 microns and less than 5 microns, such that where the formulation is administered upstream of the target tissue the ability of the active to pass through the target tissue and pass into systemic circulation is restricted.Type: ApplicationFiled: March 20, 2012Publication date: August 2, 2012Inventor: Bernardo Nadal-Ginard
-
Publication number: 20120189669Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.Type: ApplicationFiled: May 23, 2010Publication date: July 26, 2012Applicant: CARTIHEAL (2009) LTD.Inventors: Nir Altschuler, Razi Vago
-
Publication number: 20120189671Abstract: The invention provides body absorable, mechanically hemostatic putty compositions comprising carboxymethyl cellulose and one or more of polyhydroxy compounds, fatty acids, and esters thereof for use in controlling the bleeding of bone.Type: ApplicationFiled: March 2, 2012Publication date: July 26, 2012Applicant: ORTHOCON, Inc.Inventor: Richard L. Kronenthal
-
Publication number: 20120183543Abstract: The present invention provides novel methods of inhibiting fibrosis, as well as methods of treating or inhibiting fibrotic disorders, using BMP9 and/or BMP10 antagonists. The present invention also provides methods of assessing whether a subject has or is at risk of developing a fibrotic disorder by detecting levels of BMP9 and/or BMP10. Further provided are methods of assessing the efficacy of a treatment regimen for treating a fibrotic disorder by detecting and comparing pre-treatment levels of BMP9 and BMP10 with post-treatment levels of BMP9 and BMP10.Type: ApplicationFiled: May 7, 2010Publication date: July 19, 2012Applicant: NOVARTIS AGInventors: Alan Buckler, Chao-Min Chen, Chantale T. Guy, Jeffrey Hewett
-
Publication number: 20120184490Abstract: The use of autogenous bone graft is the current gold standard in the 1.5 million bone-grafting surgeries performed annually in the United States. Although this practice has resulted in high rates of fusion success, it is associated with increased operative time and blood loss, along with a significant degree of donor-site morbidity. Additionally, in certain settings such as revision cases, multilevel constructs, or in patients with medical comorbidities, autogenous bone graft may exist in limited quantity and quality. This significant need for a suitable alternative to autogenous bone graft has stimulated great interest in the exploration of bone graft substitutes and extenders.Type: ApplicationFiled: June 23, 2010Publication date: July 19, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Samuel S. Murray, Elsa Murray, Jeffrey Wang, Keyvan Behnam
-
Publication number: 20120177702Abstract: This invention provides aragonite- and calcite-based scaffolds for the repair, regeneration, enhancement of formation or a combination thereof of cartilage and/or bone, which scaffolds comprise at least two phases, wherein each phase differs in terms of its chemical content, or structure, kits comprising the same, processes for producing solid aragonite or calcite scaffolds and methods of use thereof.Type: ApplicationFiled: May 23, 2010Publication date: July 12, 2012Applicant: CARTIHEAL (2009) LTD.Inventors: Nir Altschuler, Razi Vago
-
Publication number: 20120178684Abstract: The present invention discloses a surgical cement and a manufacturing method thereof. The surgical cement comprises a cementing component selected form the group of a basic calcium phosphate consisting of tetracalcium phosphate, alpha-tricalcium phosphate, decomposed hydroxyapatite, or a combination thereof; a setting reagent selected form the group of an acidic calcium citrate consisting of monocalcium citrate, dicalcium citrate, or a combination thereof; and water; wherein a weight ratio of the cementing component and the setting reagent ranges from about 1:1 to about 8:1. The surgical cement is bioresorbable and bioactive and is useful in orthopedic, maxillofacial and dental applications. In addition, the surgical cement of this invention has a good flow character and a relatively short setting time.Type: ApplicationFiled: January 11, 2011Publication date: July 12, 2012Applicant: MAXIGEN BIOTECH INC.Inventors: SUNG-TSUEN LIU, SUNG-CHING CHEN, HUI-CHUN LAI, KEHSIN CHIEN
-
Publication number: 20120171257Abstract: Disclosed are methods for producing cell-guiding fibroinductive and angiogenic tissue engineering scaffolds composed of biodegradable and biocompatible natural biopolymers, synthetic polymers and/or their combination, incorporating growth and differentiation factors, growth hormone and chemoattractants, with interconnected pores and channels-containing microarchitecture inducing the regenerative cell migration, adhesion, proliferation and differentiation from the healthy tissues surrounding the periodontal defects, thereby facilitating the functional periodontal tissue regeneration. The methods for the application of the cell-guiding fibroinductive and angiogenic scaffolds in the surgical treatment of periodontal tissue defects resulted from destructive periodontal diseases are also provided.Type: ApplicationFiled: September 12, 2009Publication date: July 5, 2012Inventors: Bülend Inanç, Levent Inanç
-
Publication number: 20120165257Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: ApplicationFiled: December 28, 2010Publication date: June 28, 2012Applicant: DEPUY MITEK, INC.Inventors: Ben Byers, Dongling Su, Julia Hwang
-
Publication number: 20120165731Abstract: Methods and compositions are disclosed for an intra-articular injection for the treatment of osteoarthritis. The methods and compositions comprising combinations of hyaluronic acid and a bone morphogenetic protein, like rhGDF-5, can be useful for any synovial joint, including the knee, shoulder, hip, ankle, hands, spinal facet, or temporomandibular joint, both for the relief of pain and for slowing disease progression.Type: ApplicationFiled: December 28, 2010Publication date: June 28, 2012Applicant: DePuy Mitek, Inc.Inventors: Ben Byers, Dongling Su, Julia Hwang
-
Publication number: 20120156164Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: ApplicationFiled: September 2, 2010Publication date: June 21, 2012Applicant: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATIONInventors: Ki-Dong Park, Yoon-ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20120149641Abstract: Methods and compositions are described to regenerate cartilage in a partial thickness defect or area of reduced volume of articular cartilage comprising an infiltration suppressor agent and a columnar growth promoting agent.Type: ApplicationFiled: February 21, 2012Publication date: June 14, 2012Applicant: GENERA ISTRAZIVANJA d.o.o.Inventors: Slobodan VUKICEVIC, Mislav JELIC
-
Publication number: 20120148539Abstract: Disclosed herein are methods and compositions for promoting endochondral bone formation. The invention includes methods of promoting endochondral bone formation by down-regulating the expression of the DIO2 gene or the activity of the deiodinase protein. The invention also includes methods of up-regulating the activity of the FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 genes and/or the activity of the expression products of those genes to promote endochondral bone formation. The invention also includes compositions of BMP-7 and agonists of FGFR3, ADAMTS9, HEY1, HAS3, and/or MFI2 proteins. Compositions can further include mesenchymal stem cells.Type: ApplicationFiled: February 19, 2010Publication date: June 14, 2012Inventor: Moulay Hicham Alaoui-Ismaili
-
Publication number: 20120148529Abstract: The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations. In addition, the invention also relates to the administration of a cell or a pharmaceutical composition comprising inclusion bodies formed by therapeutic proteins. These inclusion bodies formed by therapeutic proteins could be used for the treatment of different diseases.Type: ApplicationFiled: May 12, 2010Publication date: June 14, 2012Applicants: Centro de Invesigacion Biomedica en Red en Bioiagenieria, Biomateriales, y Nanomedicina (Cibe, Universitat Autonoma de Barcelona et al.Inventors: Elena Garcia-Fruitos, Esther Vazquez Gomez, Jose Luis Corchero, Antonio Pedro Villa Verde Corrales
-
Patent number: 8198237Abstract: Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7.Type: GrantFiled: May 14, 2008Date of Patent: June 12, 2012Assignee: Stryker CorporationInventor: Niles Ron
-
Publication number: 20120141555Abstract: The present invention relates to compositions devices and methods for treating bone and/or cartilage defects, and a method for manufacturing such a composition or device. In a certain embodiment, the invention provides a device and/or composition for treating bone and/or cartilage defects, having at least one collagen, for example of animal origin, and further containing at least one substance having an osteo-inductive or chondro-inductive activity, at least one differentiation and/or growth factor having osteo-stimulative and/or chondro-stimulative effect, and at least one filling material, in which the composition is in the form of a lyophil.Type: ApplicationFiled: January 24, 2012Publication date: June 7, 2012Inventor: Arne Briest
-
Publication number: 20120141557Abstract: Osteogenic sponge compositions having enhanced osteoinductive properties for use in bone repair are described. The compositions include a quickly resorbable porous carrier, a more slowly resorbed mineral scaffold and an osteogenic factor, preferably a bone morphogenetic protein. The compositions enable increased osteoinductive activity while retaining a reliable scaffold for the formation of new bone at an implant site. Methods for therapeutic use of the compositions are also described.Type: ApplicationFiled: February 9, 2012Publication date: June 7, 2012Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20120141430Abstract: The present invention relates to a membrane comprising at least one positively charged, synthetic, hydrophobic polymer, at least one hydrophilic polymer and at least one plasticizer; wherein said membrane is flexible and is capable of supporting at least one of cell adherence, cell proliferation or cell differentiation. The invention further relates to use of a membrane of the invention in the preparation of an implantable devices including cell delivery systems, cell growing surfaces and scaffolds. The invention further provides methods for promoting tissue regeneration in a defected tissue region applying membranes of the invention.Type: ApplicationFiled: January 12, 2010Publication date: June 7, 2012Inventors: Michael Friedman, Yoel Sasson, Ada Grin, Rami Mosheiff, Jacob Rachmilewitz
-
Publication number: 20120141558Abstract: Alginate nanofibers, scaffolds that include alginate nanofibers, implantable devices that include alginate nanofibers, and methods for making the alginate nanofibers by electrospinning.Type: ApplicationFiled: February 9, 2012Publication date: June 7, 2012Applicant: UNIVERSITY OF WASHINGTONInventors: Miqin Zhang, Narayan Bhattarai
-
Patent number: 8193312Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2, as do endogenous forms of BBP, and sequence conservation between species results in a variety of useful BBP compositions. BBP increases the over-all osteogenic activity of rhBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: November 16, 2007Date of Patent: June 5, 2012Assignees: The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Samuel S. Murray, Elsa J. Murray, Jeffrey C. Wang, Keyvan Behnam
-
Publication number: 20120135927Abstract: The present disclosure relates to compositions and methods for treating insulin resistance and/or obesity in a cell and/or a subject.Type: ApplicationFiled: May 21, 2010Publication date: May 31, 2012Applicant: JOSLIN DIABETES CENTER, INC.Inventors: Yu-Hua Tseng, C. Ronald Kahn
-
Patent number: 8188226Abstract: The application relates to novel biosynthetic growth factor mutants, derived from GDF-5, which exhibit improved biological activity. Mutations at positions 453 and 456 of human GDF-5 are disclosed, as well as use of these mutants in therapy of diseases associated with tissue degeneration/destruction.Type: GrantFiled: November 17, 2006Date of Patent: May 29, 2012Assignee: Biopharm Gesellschaft zur biotechnologischen Entwicklung von Pharmaka mbHInventors: Jens Pohl, Frank Ploeger, Michael Kruse
-
Patent number: 8188219Abstract: A cyclized peptide designated BMP Binding Peptide (BBP) is a synthetic peptide that avidly binds rhBMP-2. BBP increases the over-all osteogenic activity of rgBMP-2, increases the rate at which rhBMP-2 induces bone formation, and BBP induces calcification alone. Compositions and substrates including BBP, and methods of using BBP are useful in therapeutic, diagnostic and clinical applications requiring calcification and osteogenesis.Type: GrantFiled: January 28, 2005Date of Patent: May 29, 2012Assignees: The Regents of the University of California, Department of Veterans AffairsInventors: Samuel S. Murray, Keyvan Behnam, Elsa J. Brochmann-Murray
-
Patent number: 8188038Abstract: An osteogenic composition is provided for implantation at or near a target tissue site beneath the skin, the osteogenic composition comprising a growth factor and a coloring agent, wherein the coloring agent imparts color to the growth factor to allow the user to see the growth factor at or near the target tissue site. In some embodiments, a method is provided for accelerating bone repair, the method comprising mixing bone morphogenic protein-2 and a coloring agent to form a mixture; applying the mixture to a surface of a porous collagen matrix, wherein the coloring agent allows the user to see bone morphogenic protein-2 distribution on or in the porous collagen matrix; and implanting the porous collagen matrix at or near a target tissue site in need of bone repair.Type: GrantFiled: August 1, 2011Date of Patent: May 29, 2012Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20120129761Abstract: A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising a) providing a bone cement powder comprising calcium sulfate hemihydrate, an accelerator for the hardening of the calcium sulfate hemihydrate by hydration, said accelerator being selected from the group consisting of saline and calcium sulfate dihydrate, and a powdered calcium phosphate component b) mixing the bone cement powder with the aqueous liquid for a period of time c) leaving the mixture for the time needed for allowing the hydration reaction of the calcium sulfate hemihydrate to proceed and allowing calcium sulfate dihydrate crystals to form and grow, and d) admixing the additive by means of a short-duration mType: ApplicationFiled: February 8, 2011Publication date: May 24, 2012Inventors: Veronica Sandell, Malin Nilsson, Eva Liden, Jeffrey C. Karr